永井博弌
Proc Natl Acad Sci USA. 2006; 103(1): 153-158.
12) Nagai H .Immunopharmacological approach to elucidating the mechanism of allergic inflammation. Allergol Int 2005; 54(2): 251-261.(Review)
13) Nagai H, Tanaka H, Inagaki N, Teramachi H and Tsuchiya T. Possible role of prostaglandins in allergic inflammation Clin Exp Allergy; 7: 32-35. 2007
14) Nagai H. : Prostaglandin as a target molecule for pharmacotherapy of allergic inflammatory diseases. Allergol Int. 57(3):187-96. 2008,(Review)
15) Nagai H. Recent research and developmental strategy of anti-asthma drugs. Pharmacol Ther. 2012 Jan;133(1):70-78. (Review)
その他 論文322編、総説138編
Effect of overproduction of interleukin 5 on dinitrofluorobenzene-induced allergic cutaneous response in mice. J Pharmacol Exp Ther 1999; 288(1): 43-50
6) Nagai H, Ueda Y, Ochi T, Hirano Y, Tanaka H, Inagaki N, Kawada K.
Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice.Br J Pharmacol 2000; 129(2): 299-306.
7) Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S.;Prostaglandin D2 as a mediator of allergic asthma. Science 2000; 287(5460): 2013-2017.